New drug combo shows promise for untreated kidney cancer

NCT ID NCT01684397

Ongoing Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two drugs, pazopanib and bevacizumab, given one after the other in people with advanced kidney cancer that has spread. The goal is to find the best dose and see how well the combination works. About 51 patients who have not had prior treatment will take part. The drugs work by blocking blood flow to tumors and stopping cancer cell growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pazopanib hydrochloride and bevacizumab
What this could lead to: If successful, this could offer a new treatment option for people with advanced kidney cancer that has spread, potentially improving how long the cancer is kept under control.
What could go wrong: This is an early-phase trial with only 51 participants, so results may not apply to everyone. The combination may cause serious side effects, and it is not yet known if it works better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA STAGE IV RENAL CELL CANCER

Contacts and locations

Locations

Karamanos Cancer Institute

Detroit, Michigan, 482018, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
The University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.